NuSirt Sciences Inc

NuSirt BioPharma is a privately held biopharmaceutical company headquartered in Nashville TN with research labs in Knoxville, TN. NuSirt is focused on the development of novel drugs for the treatment of diabetes and other metabolic disorders including obesity, arteriosclerosis, and hyperlipidemia. NuSirts first product, NS-0100, uses NuSirts platform technology to combined the natural product leucine with a very low dose of metformin for the treatment of type II diabetes. Although, metformin is the gold standard in the treatment of early type II diabetes many patients can not tolerate the adverse gastrointestinal side effects metformin can cause in some patients. Consequentially these patients wither become non compliant in their medication regime or are switched to more potent and costly therapeutics. NuSirt is currently testing varying doses of NS-0100 in a Phase 2 clinical study to find the most efficacious dose of this new combination. If NuSirts clinical trials are successful NS-0100 may offer patients a viable alternative to metformin